{"id":"pure-chemotherapy-xelox","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"10-20","effect":"Hand-foot syndrome"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL1164920","moleculeType":"Small molecule","molecularWeight":"364.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is a fluoropyrimidine carbamate that is converted to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and disrupts nucleotide synthesis. Oxaliplatin is a platinum-based agent that forms DNA adducts and cross-links, preventing DNA replication and transcription. Together, these agents provide synergistic cytotoxic effects against cancer cells.","oneSentence":"Xelox is a chemotherapy regimen combining capecitabine and oxaliplatin that inhibits DNA synthesis and causes DNA cross-linking to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:41.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Gastric cancer"},{"name":"Breast cancer (adjuvant and metastatic settings)"}]},"trialDetails":[{"nctId":"NCT02748772","phase":"PHASE3","title":"Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical","status":"UNKNOWN","sponsor":"The First People's Hospital of Hefei","startDate":"2016-01","conditions":"Colorectal Neoplasms","enrollment":148}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CapeOX"],"phase":"phase_3","status":"active","brandName":"Pure chemotherapy（Xelox）","genericName":"Pure chemotherapy（Xelox）","companyName":"The First People's Hospital of Hefei","companyId":"the-first-people-s-hospital-of-hefei","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xelox is a chemotherapy regimen combining capecitabine and oxaliplatin that inhibits DNA synthesis and causes DNA cross-linking to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Gastric cancer, Breast cancer (adjuvant and metastatic settings).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}